📄 TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.

COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.

keywords 🔗 COVID-19 (1240) 🔗 Cytokine storm (25) 🔗 JAK2 inhibitor (2) 🔗 SARS-CoV-2 (551) 🔗 TH17 (1) 🔗 high mortality (78)

download 🔖 [BibTeX]